Single center, retrospective study evaluating prognostic ability of skeletal muscle density in ipilimumab treated malignant melanoma patients using computed tomography (CT) imaging.

Trial Profile

Single center, retrospective study evaluating prognostic ability of skeletal muscle density in ipilimumab treated malignant melanoma patients using computed tomography (CT) imaging.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2016 New trial record
    • 11 Oct 2016 Results of retrospective cutpoint analysis examining the prognostic ability of SMD in ipilimumab-treated MM patients presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top